STOCK TITAN

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Rani Therapeutics (Nasdaq: RANI), a clinical-stage biotherapeutics company specializing in oral delivery of biologics and drugs, has scheduled the release of its fourth quarter and full year 2024 financial results on Monday, March 31, 2025, after market close.

The company will host a conference call and webcast at 4:30 p.m. ET / 1:30 p.m. PT on the same day. Interested parties can access the webcast through the 'Investors' section of Rani's website at www.ranitherapeutics.com. A replay will be available in the investor relations section following the call.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction 1 Alert

-0.69% News Effect

On the day this news was published, RANI declined 0.69%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN JOSE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2024 and provide a business update on Monday, March 31, 2025 after the close of trading. Rani’s management team will host a conference call and webcast beginning at 4:30 p.m. ET.

Conference Call and Webcast

Rani Therapeutics will host a conference call and live webcast at 4:30 p.m. ET / 1:30 p.m. PT on March 31, 2025. Individuals interested in listening to the live conference call may do so by using the webcast link in the “Investors” section of the company’s website at www.ranitherapeutics.com. A webcast replay will be available in the investor relations section on the company’s website following the completion of the call.

About Rani Therapeutics

Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology. For more information, visit ranitherapeutics.com.

Investor Contact:

investors@ranitherapeutics.com

Media Contact:

media@ranitherapeutics.com


FAQ

When will Rani Therapeutics (RANI) release Q4 and full year 2024 earnings?

Rani Therapeutics will release Q4 and full year 2024 financial results on Monday, March 31, 2025, after market close.

What time is Rani Therapeutics (RANI) Q4 2024 earnings call?

The earnings conference call and webcast is scheduled for March 31, 2025, at 4:30 p.m. ET / 1:30 p.m. PT.

How can investors access Rani Therapeutics (RANI) Q4 2024 earnings call?

Investors can access the webcast through the 'Investors' section of www.ranitherapeutics.com. A replay will be available afterward.

What is Rani Therapeutics' (RANI) main business focus?

Rani Therapeutics is a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs.
Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

RANI Rankings

RANI Latest News

RANI Latest SEC Filings

RANI Stock Data

148.28M
91.95M
19.56%
17.01%
0.22%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN JOSE